Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H27NO.ClH |
| Molecular Weight | 357.917 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=GTRBFCLXPXZLPA-QYESKELBSA-N
InChI=1S/C22H27NO.ClH/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18;/h3-12,19-22H,2,13-16H2,1H3;1H/t19-,20+,21+;
| Molecular Formula | C22H27NO |
| Molecular Weight | 321.4559 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Ethybenzatropine (Ponalid) is an anticholinergic and antihistaminergic drug. It was used as an antiparkinsonian agent. A significant increase in the duration of action of levodopa-induced improvement in parkinsonian symptoms was observed following the administration of ethybenzatropine. Ethybenzatropine also improved, or tended to improve the duration and seventy of onset and end-of-dose levodopa-induced dyskinesias. Thus when levodopa is administered together with etybenzatropine, its length of action on parkinsonian symptoms is prolonged.
Approval Year
Sample Use Guides
Nine patients with Parkinson’s disease: Levodopa was given orally
together with a peripheral DOPA-decarboxylase inhibitor at the usual effective morning dosage for each patient. The same dose of levodopa was administered the next day in addition to ethybenzatropine, 5 mg given i.v. Ethybenzatropine was administered between 0 and 15 min after the first dose of levodopa
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:54:57 GMT 2025
by
admin
on
Mon Mar 31 21:54:57 GMT 2025
|
| Record UNII |
O2J107X51K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
26598-44-7
Created by
admin on Mon Mar 31 21:54:57 GMT 2025 , Edited by admin on Mon Mar 31 21:54:57 GMT 2025
|
PRIMARY | |||
|
SUB02050MIG
Created by
admin on Mon Mar 31 21:54:57 GMT 2025 , Edited by admin on Mon Mar 31 21:54:57 GMT 2025
|
PRIMARY | |||
|
m5080
Created by
admin on Mon Mar 31 21:54:57 GMT 2025 , Edited by admin on Mon Mar 31 21:54:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000087480
Created by
admin on Mon Mar 31 21:54:57 GMT 2025 , Edited by admin on Mon Mar 31 21:54:57 GMT 2025
|
PRIMARY | |||
|
O2J107X51K
Created by
admin on Mon Mar 31 21:54:57 GMT 2025 , Edited by admin on Mon Mar 31 21:54:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
